Lindbrook Capital’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Lindbrook Capital’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,000	Closed	-$40.6K	–	2965
2022 Q4	$40.6K	Buy	2,000 +1,500	+300%	+$23K	0.01%	770
2022 Q3	$5K	Hold	500	–	–	﹤0.01%	1715
2022 Q2	$6K	Hold	500	–	–	﹤0.01%	1513
2022 Q1	$11K	Hold	500	–	–	﹤0.01%	1265
2021 Q4	$17K	Hold	500	–	–	﹤0.01%	1092
2021 Q3	$13K	Hold	500	–	–	﹤0.01%	912
2021 Q2	$7K	Hold	500	–	–	﹤0.01%	1220
2021 Q1	$5K	Hold	500	–	–	﹤0.01%	1294
2020 Q4	$4K	Hold	500	–	–	﹤0.01%	1298
2020 Q3	$4K	Hold	500	–	–	﹤0.01%	1227
2020 Q2	$5K	Hold	500	–	–	﹤0.01%	1114
2020 Q1	$5K	Hold	500	–	–	﹤0.01%	1039
2019 Q4	$7K	Hold	500	–	–	﹤0.01%	1036
2019 Q3	$8K	Hold	500	–	–	﹤0.01%	974
2019 Q2	$6K	Hold	500	–	–	﹤0.01%	1033
2019 Q1	$6K	Buy	+500	New	+$7.29K	﹤0.01%	1054

Lindbrook Capital's OPNT Position: Q1 2023 in Review

Lindbrook Capital sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 2,000 shares — an estimated $40.6K sold.

Lindbrook Capital first reported a position in OPNT in Q1 2019 and held it in 16 quarters. The position peaked at $40.6K in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Lindbrook Capital reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Lindbrook Capital sold 2,000 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $40.6K.
Lindbrook Capital first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 16 quarters.
Lindbrook Capital's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $40.6K in Q4 2022.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Lindbrook Capital's 13F filing for Q1 2023, filed 26 Apr 2023.